A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.

1986 ◽  
Vol 4 (10) ◽  
pp. 1455-1461 ◽  
Author(s):  
R Lee ◽  
F Cabanillas ◽  
G P Bodey ◽  
E J Freireich
Keyword(s):  
Cell Lymphoma ◽  
Large Cell ◽  
High Dose ◽  
Diffuse Large Cell Lymphoma ◽  
Actuarial Survival ◽  
Conventional Dose ◽  
Long Term Follow Up ◽  
Large Cell Lymphoma

Long-term follow-up results of two studies using cyclophosphamide, doxorubicin, vincristine, and prednisone plus bleomycin (CHOP-Bleo) for the treatment of diffuse large-cell lymphoma are presented. Twenty-eight patients were treated with conventional-dose CHOP-Bleo and 36 patients with maximally tolerated doses of CHOP-Bleo. The maximal duration of follow-up was 10.5 years. The minimum follow-up was 5.7 years. Seventy-five percent of the conventional-dose group achieved a complete remission (CR) with a 10-year actuarial survival of 53% and a corresponding relapse-free survival (RFS) of 69% for CRs. Eighty-one percent of the high-dose group achieved CR, and the 10-year actuarial survival for all patients and RFS for CRs were 48% and 63%, respectively. The combined actuarial survival and RFS for both groups were 51% and 66%, respectively, at 10 years. For 11 patients with stage III disease, 91% achieved CR, 52% survived at 10 years, and the RFS was 67% for CRs. Seventy-five percent of 44 patients with stage IV disease achieved CR, 50% survived at 10 years, and the RFS was 67% for CRs. Three of the 16 relapses occurred late, between 30 to 65 months after initiation of therapy. Neuropathy occurred in 14 patients (22%). Five patients (8%) died of complications related to treatment. Five (8%) had clinically apparent, but nonfatal cardiopulmonary complications. The CHOP-Bleo regimen is an effective treatment for diffuse large-cell lymphoma, and is moderately well tolerated. The use of high-dose CHOP-Bleo for induction therapy did not result in any advantage after long-term follow-up.

Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.

1989 ◽  
Vol 7 (9) ◽  
pp. 1186-1191 ◽  
Author(s):  
S E Jones ◽  
T P Miller ◽  
J M Connors
Keyword(s):  
Prognostic Factors ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Diffuse Large Cell Lymphoma ◽  
Relapse Free Survival ◽  
Bulky Disease ◽  
Free Survival ◽  
Large Cell Lymphoma

In order to assess long-term outcome of patients with localized (stage I or II) diffuse large-cell lymphoma treated with initial combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without involved-field radiotherapy following chemotherapy, we combined data from two prospective trials in Tucson (64 patients) and Vancouver (78 patients). Follow-up on 142 patients was updated and a variety of potential pretreatment prognostic factors were analyzed for impact on outcome. One hundred forty patients (99%) achieved a complete remission and there were no differences in outcome between institutions. Twenty-three patients have relapsed and 22 have died from lymphoma at a median follow-up of 4.4 years, resulting in an overall relapse-free survival of 82% at 5 years. There was no treatment-related mortality and were no instances of late cardiac toxicity or leukemia. Of the following potential pretreatment prognostic factors (age, stage, "B" symptoms, extranodal disease, gastrointestinal tract involvement, bulky disease, or disease above or below the diaphragm), only stage affected relapse-free survival (RFS) (P = .16) and survival (.003). Among 34% of patients over age 65, outcome was similar to younger patients. RFS for 108 patients treated with CHOP plus radiotherapy was not significantly superior to the use of CHOP alone in 34 patients (P = .2).

scholarly journals Follicular large cell lymphoma: Long-term follow-up of 62 patients treated between 1973–1981

2000 ◽  
Vol 11 (12) ◽  
pp. 1551-1556 ◽  
Author(s):  
J. Rodriguez ◽  
P. McLaughlin ◽  
L. Fayad ◽  
M. Santiago ◽  
M. Hess ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Large Cell ◽  
Long Term Follow Up ◽  
Large Cell Lymphoma

Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1565-1565 ◽  
Author(s):  
Paola Ghione ◽  
Peter G. Cordeiro ◽  
Ai Ni ◽  
Qunying Hu ◽  
Nivetha Ganesan ◽  
...  
Keyword(s):  
Breast Reconstruction ◽  
Cell Lymphoma ◽  
Breast Implant ◽  
Breast Implants ◽  
Large Cell ◽  
Long Term Follow Up ◽  
Large Cell Lymphoma ◽  
Prospective Database

1565 Background: Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare subtype of T-cell lymphoma, developing in in the fluid or capsule surrounding breast implants, primarily or exclusively in those with textured surfaces. Several prior series have estimated the risk of BIA- ALCL at 1/6920 - 1/3800 women in retrospectively defined cohorts (from diagnosed cases within national or pathology databases), approximating the population at risk from sales records or other estimates (Sirinvasa 2017; Loch-Wilkinson 2017; de Boer 2018). Methods: A prospective cohort study was conducted in the population that underwent breast reconstruction by a single surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) from April 1993 to December 2017. Patients had long-term follow-up, and events related to implants were prospectively recorded. We identified all cases of BIA-ALCL by cross-checking data from internal clinical records, pathology records, and outside reports. Incidence rate per person-years and cumulative incidence when accounting for competing risk were calculated. 134 women who received smooth-surface implants were excluded from the analysis, since these implants have not been associated with BIA-ALCL. Results: From 1993 to 2017, 3546 patients underwent 6023 breast reconstructions using textured surface implants. All reconstructions were performed by a single surgeon (PGC) on patients enrolled in this study. To identify BIA-ALCL occurrence, clinical and pathological data were assessed from a prospective database. Median follow-up was 7 years (range, 3 days - 24.7 years). Eight women developed ALCL after a median exposure of 11.2 years (range, 8.3-15.8 years). Overall risk of BIA-ALCL in this cohort was 0.294 cases per 1000 person-years (1/443 women). Conclusions: This study, evaluating the risk of women with textured breast implants from a prospective database with long-term follow-up, demonstrated that the incidence rate of BIA-ALCL may be higher than previously reported. These results can help inform implant choice for women undergoing breast reconstruction.

Primary cutaneous anaplastic large cell lymphoma (pcALCL): Initial approach and long-term follow-up in 108 patients.

2018 ◽  
Vol 101 ◽  
pp. S19-S20
Author(s):  
Ricardo Fernández-de-Misa ◽  
Buenaventura Hernández-Machín ◽  
Andrea Combalia ◽  
María del Pilar García-Muret ◽  
Octavio Servitje ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Initial Approach ◽  
Long Term Follow Up ◽  
Large Cell Lymphoma

Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment.

1989 ◽  
Vol 7 (9) ◽  
pp. 1281-1287 ◽  
Author(s):  
S J Horning ◽  
E K Carrier ◽  
R V Rouse ◽  
R A Warnke ◽  
S A Michie
Keyword(s):  
Cell Lymphoma ◽  
Large Cell ◽  
Diagnostic Techniques ◽  
Response To Treatment ◽  
Common Antigen ◽  
Diffuse Large Cell Lymphoma ◽  
Actuarial Survival ◽  
Leukocyte Common Antigen ◽  
Large Cell Lymphoma ◽  
Immunohistochemical Techniques

Malignant lymphoma is frequently diagnosed when immunohistochemical techniques are applied to otherwise unclassified neoplasms. In this analysis of 35 patients with a histologically unclassified neoplasm that expressed leukocyte-common antigen(s) (LCA), actuarial survival was 63%, and 45% of patients were free from disease progression at 30 months following treatment as for lymphoma. The clinical features at diagnosis and the results of combination chemotherapy were found to be similar to a group of patients with a diagnosis of diffuse large-cell lymphoma (DLCL) concurrently treated at this institution. This study further emphasizes the importance of improved diagnostic techniques in the management of histologically unclassified tumors.

Delphi-Panel Analysis of Appropriateness of High-Dose Chemotherapy and Blood Cell or Bone Marrow Autotransplants in Diffuse Large-Cell Lymphoma

1998 ◽  
Vol 32 (1-2) ◽  
pp. 139-149 ◽  
Author(s):  
Robert Peter Gale ◽  
Rolla Edward Park ◽  
Robert Dubois ◽  
Philip Jay Bierman ◽  
Richard I. Fisher ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Blood Cell ◽  
Cell Lymphoma ◽  
Large Cell ◽  
High Dose Chemotherapy ◽  
Delphi Panel ◽  
High Dose ◽  
Panel Analysis ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document